Finance

The Old Enemy: Aging

The last ten years’ progress in biotechnology and medicine has outpaced the previous ten years significantly. The same thing is true of the ten years prior to that ten years. The next ten years, it’s safe to say, will see greater progress than any other period in history. Powered by exponential advances in the biological…

Fear Your Platinum American Express Card

Afraid you won’t have enough to retire comfortably? You’re not alone, and a debt-fueled lifestyle is often a big part of the problem. As the 2014 EBRI Retirement Confidence Survey notes: Fifty-eight percent of workers and 44 percent of retirees report having a problem with their level of debt. Furthermore, 24 percent of workers and…

EC The Importa

There were two developments today that are important for investors to know about before the markets open on Friday to close the month.   First, and most importantly, the results of the OPEC meeting are the most negative outcome for prices. OPEC, which over-produced in October, decided to roll-over the existing quota 30 mln barrels a day….

The Upcoming Utility Shakeout

Investing Daily Article of the Week by Richard Stavros With more and more utilities trading at premium valuations, now is the time for investors to diversify their portfolios into the sector’s higher-quality names. That’s my conclusion after attending the Edison Electric Institute Financial Conference last week, an annual event hosted by the association of investor-owned…

NewLink Genetics Scores Partnership With Merck For Experimental E

On Monday November 24th 2014 NewLink Genetics (NLNK) had announced that it had entered into a partnership agreement with Merck (MRK) to co-develop an experimental vaccine for Ebola known as rVSV-EBOV. Under the terms of the agreement Merck will pay an upfront payment to NewLink for $50 million dollars plus additional money from royalty on the Ebola candidate once…